Attention AACR Annual Meeting 2017 Registrants – Activate Your Access

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

  • Sort by:
  • Browse by:
<< first | < prev page: of 4 records per page: next > | last >>
pages: 1 2 3 4 presentations: 1 to 25 of 89
Preventing multiple types of cancer through HPV vaccination
Douglas R. Lowy
National Cancer Institute, Bethesda, MD, United States
from 2011 Molecular Targets and Cancer Therapeutics conference on November 12, 2011 1:30 PM-3:30 PM
Chemoprevention of lung cancer with prostacyclins or PPAR gamma agonists
Paul A. Bunn
University of Colorado Denver, Aurora, CO, United States
from 2011 Molecular Targets and Cancer Therapeutics conference on November 12, 2011 1:30 PM-3:30 PM
Use of presurgical models to screen active agents for breast intraepithelial neoplasia
Andrea De Censi
E.O. Ospedali Galliera, Genova, Italy
from 2011 Molecular Targets and Cancer Therapeutics conference on November 12, 2011 1:30 PM-3:30 PM
Cancer interception and reverse migration
Scott M. Lippman
University of Texas MD Anderson Cancer Center, Houston, TX, United States
from 2011 Molecular Targets and Cancer Therapeutics conference on November 12, 2011 1:30 PM-3:30 PM
New paradigms for early-phase clinical trials
James H. Doroshow
National Cancer Institute, Bethesda, MD, United States
from 2011 Molecular Targets and Cancer Therapeutics conference on November 12, 2011 3:30 PM-5:30 PM
Phasing out phase III trials: How much evidence do we need if the target is clearly hit?
Jaap Verweij
Erasmus University Medical Center - Daniel den Hoed Cancer Center, Rotterdam, Netherlands
from 2011 Molecular Targets and Cancer Therapeutics conference on November 12, 2011 3:30 PM-5:30 PM
Development of clinical trials incorporating genomic signatures: Lessons learned
Lisa M McShane
National Cancer Institute, Bethesda, MD, United States
from 2011 Molecular Targets and Cancer Therapeutics conference on November 12, 2011 3:30 PM-5:30 PM
Clinical trial designs for targeted therapies
John J. Crowley
Cancer Research and Biostatistics, Seattle, WA, United States
from 2011 Molecular Targets and Cancer Therapeutics conference on November 12, 2011 3:30 PM-5:30 PM
Chairperson
Kenneth C. Anderson
Dana-Farber Cancer Institute, Boston, MA, United States
from 2011 Molecular Targets and Cancer Therapeutics conference on November 13, 2011 8:00 AM-10:05 AM
Chairperson
James H. Doroshow
National Cancer Institute, Bethesda, MD, United States
from 2011 Molecular Targets and Cancer Therapeutics conference on November 13, 2011 8:00 AM-10:05 AM
Chairperson
Stefan Sleijfer
Erasmus Medical Center, Rotterdam, Netherlands
Presentation given by
Jean-Yves Blay
Centre Léon Bérard, Lyon, France
from 2011 Molecular Targets and Cancer Therapeutics conference on November 13, 2011 8:00 AM-10:05 AM
Overcoming barriers to new drug development
William N. Hait
Johnson & Johnson Pharmaceutical R&D, Raritan, NJ, United States
from 2011 Molecular Targets and Cancer Therapeutics conference on November 13, 2011 8:00 AM-10:05 AM
Genomic profiling for personalized medicine
P. Andrew Futreal
Wellcome Trust Sanger Institute, Cambridge, United Kingdom
from 2011 Molecular Targets and Cancer Therapeutics conference on November 13, 2011 8:00 AM-10:05 AM
Combinatorial approaches to prevent adoptive responses to targeted therapeutics in breast cancer
José Baselga
Massachusetts General Hospital Cancer Center, Boston, MA, United States
from 2011 Molecular Targets and Cancer Therapeutics conference on November 13, 2011 10:30 AM-12:30 PM
Optimizing targeted treatment of EGFR mutant lung cancer
William Pao
Vanderbilt University, Nashville, TN, United States
from 2011 Molecular Targets and Cancer Therapeutics conference on November 13, 2011 10:30 AM-12:30 PM
Predicting response and resistance to targeted anticancer therapeutics
Levi A. Garraway
Dana-Farber Cancer Institute, Boston, MA, United States
from 2011 Molecular Targets and Cancer Therapeutics conference on November 13, 2011 10:30 AM-12:30 PM
The neoadjuvant model in breast cancer research: stories of success
Serena Di Cosimo
Vall d'Hebron University Hospital, Barcelona, Spain
from 2011 Molecular Targets and Cancer Therapeutics conference on November 13, 2011 10:30 AM-12:30 PM
Changing cell fate in cancer: Lessons from melanoma
Leonard I. Zon
Harvard Medical School, Children's Hospital, Boston, MA, United States
from 2011 Molecular Targets and Cancer Therapeutics conference on November 13, 2011 2:30 PM-4:30 PM
BRAF and RAS signaling in cancer: From biology to therapeutics
Richard M. Marais
Institute of Cancer Research, London, United Kingdom
from 2011 Molecular Targets and Cancer Therapeutics conference on November 13, 2011 2:30 PM-4:30 PM
BRAF and MEK inhibition in melanoma
Tona M. Gilmer
GlaxoSmithKline, Research Triangle Park, NC, United States
from 2011 Molecular Targets and Cancer Therapeutics conference on November 13, 2011 2:30 PM-4:30 PM
ERK pathway inhibitors in melanoma -- sensitivity and resistance
Neal Rosen
Memorial Sloan-Kettering Cancer Center, New York, NY, United States
from 2011 Molecular Targets and Cancer Therapeutics conference on November 13, 2011 2:30 PM-4:30 PM
Acquired resistance to RAF inhibitors is mediated by splicing isoforms of BRAF(V600E) that dimerize in a RAS-independent manner.
Poulikos I. Poulikakos
Memorial Sloan-Kettering Cancer Center, New York, NY, United States
from 2011 Molecular Targets and Cancer Therapeutics conference on November 13, 2011 4:30 PM-6:00 PM
KRAS mutation and amplification status predicts sensitivity to antifolate therapies in non small cell lung cancer
Sarah Bacus
Quintiles Transnational Corp., Westmont, IL, United States
from 2011 Molecular Targets and Cancer Therapeutics conference on November 13, 2011 4:30 PM-6:00 PM
Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: Association with clinical endpoints in a Phase II clinical trial of Pertuzumab and Erlotinib
Elizabeth Punnoose
Genentech, Inc., South San Francisco, CA, United States
from 2011 Molecular Targets and Cancer Therapeutics conference on November 13, 2011 4:30 PM-6:00 PM
Gene amplification of Anaplastic Lymphoma Kinase in Inflammatory Breast Cancer
Fredika M. Robertson
UT MD Anderson Cancer Ctr., Houston, TX, United States
from 2011 Molecular Targets and Cancer Therapeutics conference on November 13, 2011 4:30 PM-6:00 PM
<< first | < prev page: of 4 records per page: next > | last >>
pages: 1 2 3 4 presentations: 1 to 25 of 89